24 Vs 48-Week Treatment With Peg-Ifn Alpha-2a In Patients With Genotype 2/3 Chronic Hepatitis C, Relapsers To Peg-Ifn + Ribavirin Treatment. A Randomized Controlled Trial.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 19 Mar 2012 Biomarkers information updated
- 16 Mar 2012 Actual initiation date (May 2012) added as reported by ClinicalTrials.gov.
- 16 Mar 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.